RaySearch and Vision RT unveil automated RayStation®-MapRT® integration
At the ESTRO conference in Glasgow this week, RaySearch Laboratories and Vision RT unveil a new automated interface between their products, designed to help radiation treatment planners make better, safer plans for better patient outcomes.
Recent studies show that non-coplanar treatments can deliver clinically relevant improvements to dose distributions1, specifically in lung cancer²⁻⁵ breast cancer⁶⁻⁸, head and neck cancer⁹⁻¹⁵ lymphoma¹⁶, ¹⁷ and high-grade glioma¹⁸. However, clearance checks are often required to avoid collisions, especially with elbows and immobilisation outside the CT scan volume.
MapRT cameras capture the entire surface of the patient and any immobilisation accessories during CT-sim. Its software then uses this data, along with couch and treatment machine surface models, to predict which gantry and couch angles are clear to use in planning. This means that each patient has a unique “clearance map” for any chosen treatment isocentre.
With MapRT’s new Application Programming Interface (API) demonstrated at ESTRO, RayStation users will be able to access a patient’s plan clearance status with just a few mouse clicks. This API clears the way for future development of automatic plan creation and optimisation.
Norman Smith, CEO of Vision RT said “Automation is becoming more and more important in radiation oncology, and at the same time there is growing demand for personalised plans with the best possible dose distribution. The API and integration is a big step forwards in our ability to offer more automation in radiation therapy planning.”
Björn Hårdemark, RaySearch Deputy CEO, said “Surface scanning and other optical 3D imaging techniques are great sources of information that have potential to improve many areas in radiation therapy treatment planning, delivery, and follow-up. The integration between RayStation and MapRT enables a better awareness of clearances during treatment planning, which in turn allows for more elaborate beam configurations without jeopardising clearance.”
Image: MapRT’s full body clearance map within RayStation software (version not currently available for sale)
RayStation and MapRT are trademarks of RaySearch Laboratories and Vision RT respectively.
About Vision RT
With 70+ granted patents plus 50+ pending, we continue to innovate in the radiation oncology space and are committed to making SGRT the standard of care for all patients, worldwide. There are more than 1,500 systems installed worldwide. Vision RT’s first product, AlignRT, is in 24 of the top 25 US News & World Report Best Hospitals for Cancer.
Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in WDI employ more than 18,000 people, with a total revenue of more than $3 billion.
Media queries: Billy Cometti Bcometti@visionrt.com, Head of Communications
[1] Smyth G, Evans PM, Bamber JC, Bedford JL. Recent developments in non-coplanar radiotherapy. Br J Radiol. 2019 May;92(1097):20180908. doi: 10.1259/bjr.20180908. Epub 2019 Feb 1. PMID: 30694086; PMCID: PMC6580906.
[2] Ma M, Ren W, Li M, Niu C, Dai J. Dosimetric comparison of coplanar and noncoplanar beam arrangements for radiotherapy of patients with lung cancer: A meta-analysis. J Appl Clin Med Phys. 2021 Apr;22(4):34-43. doi: 10.1002/acm2.13197. Epub 2021 Feb 26. PMID: 33634946; PMCID: PMC8035566.
[3] Kim ST, An HJ, Kim JI, Yoo JR, Kim HJ, Park JM. Non-coplanar VMAT plans for lung SABR to reduce dose to the heart: a planning study. Br J Radiol. 2020 Jan;93(1105):20190596. doi: 10.1259/bjr.20190596. Epub 2019 Oct 22. PMID: 31625759; PMCID: PMC6948076.
[4] Lincoln JD, MacDonald RL, Syme A, Thomas CG. Static couch non-coplanar arc selection optimization for lung SBRT treatment planning. Phys Med Biol. 2023 Jul 21;68(15). doi: 10.1088/1361-6560/ace23f. PMID: 37369237.
[5] Chapet O, Khodri M, Jalade P, N’guyen D, Flandin I, D’hombres A, Romestaing P, Mornex F. Potential benefits of using non coplanar field and intensity modulated radiation therapy to preserve the heart in irradiation of lung tumors in the middle and lower lobes. Radiother Oncol. 2006 Sep;80(3):333-40. doi: 10.1016/j.radonc.2006.07.009. Epub 2006 Aug 24. PMID: 16934354.
[6] J, F., et al. (2023). Locoregional breast radiotherapy including IMN: optimizing the dose distribution using an automated non-coplanar VMAT-technique. Acta oncologica (Stockholm, Sweden), [online] 62(10). doi:https://doi.org/10.1080/0284186X.2023.2264488.
[7] Xu, Y., Ma, P., Hu, Z., Tian, Y., Men, K., Wang, S., Xu, Y. and Dai, J. (2021). Non-coplanar volumetric modulated arc therapy for locoregional radiotherapy of left-sided breast cancer including internal mammary nodes. Radiology and Oncology, 55(4), pp.499–507. doi:https://doi.org/10.2478/raon-2021-0045.
[8] A, B., et al. (2023). Dosimetric Comparision of Coplanar versus Noncoplanar Volumetric Modulated Arc Therapy for Treatment of Bilateral Breast Cancers. Journal of medical physics, [online] 48(3). doi:https://doi.org/10.4103/jmp.jmp_36_23.
[9] Biau J, Lopez L, Thivat E, Casile M, Millardet C, Saroul N, Pham-Dang N, Molnar I, Bourhis J, Lapeyre M. Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017-03 phase 2 trial. Clin Transl Radiat Oncol. 2022 Nov 14;38:169-174. doi: 10.1016/j.ctro.2022.11.007. PMID: 36466746; PMCID: PMC9712819.
[10] Woods KE, Ma TM, Cook KA, Morris ED, Gao Y, Sheng K, Kishan AU, Hegde JV, Felix C, Basehart V, Narahara K, Shen Z, Tenn S, Steinberg ML, Chin RK, Cao M. A Prospective Phase II Study of Automated Non-Coplanar VMAT for Recurrent Head and Neck Cancer: Initial Report of Feasibility, Safety, and Patient-Reported Outcomes. Cancers (Basel). 2022 Feb 14;14(4):939. doi: 10.3390/cancers14040939. PMID: 35205686; PMCID: PMC8870161.
[11] Rwigema JC, Nguyen D, Heron DE, Chen AM, Lee P, Wang PC, Vargo JA, Low DA, Huq MS, Tenn S, Steinberg ML, Kupelian P, Sheng K. 4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer: potential to improve tumor control and late toxicity. Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):401-9. doi: 10.1016/j.ijrobp.2014.09.043. Epub 2014 Dec 5. PMID: 25482301.
[12] Gayen S, Kombathula SH, Manna S, Varshney S, Pareek P. Dosimetric comparison of coplanar and non-coplanar volumetric-modulated arc therapy in head and neck cancer treated with radiotherapy. Radiat Oncol J. 2020 Jun;38(2):138-147. doi: 10.3857/roj.2020.00143. Epub 2020 May 26. PMID: 33012157; PMCID: PMC7533406.
[13] Subramanian VS, Subramani V, Chilukuri S, Kathirvel M, Arun G, Swamy ST, Subramanian K, Fogliata A, Cozzi L. Multi-isocentric 4π volumetric-modulated arc therapy approach for head and neck cancer. J Appl Clin Med Phys. 2017 Sep;18(5):293-300. doi: 10.1002/acm2.12164. Epub 2017 Aug 20. PMID: 28834021; PMCID: PMC5874945.
[14] Wild, E., Bangert, M., Nill, S. and Oelfke, U. (2015). Noncoplanar VMAT for nasopharyngeal tumors: Plan quality versus treatment time. Medical Physics, 42(5), pp.2157–2168. doi:https://doi.org/10.1118/1.4914863.
[15] Orlandi E, Giandini T, Iannacone E, De Ponti E, Carrara M, Mongioj V, Stucchi C, Tana S, Bossi P, Licitra L, Fallai C, Pignoli E. Radiotherapy for unresectable sinonasal cancers: dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy. Radiother Oncol. 2014 Nov;113(2):260-6. doi: 10.1016/j.radonc.2014.11.024. Epub 2014 Nov 29. PMID: 25467003.
[16] Rossi L, Cambraia Lopes P, Marques Leitão J, Janus C, van de Pol M, Breedveld S, Penninkhof J, Heijmen BJM. On the Importance of Individualized, Non-Coplanar Beam Configurations in Mediastinal Lymphoma Radiotherapy, Optimized With Automated Planning. Front Oncol. 2021 Apr 15;11:619929. doi: 10.3389/fonc.2021.619929. PMID: 33937025; PMCID: PMC8082440.
[17] Chen X, Jin D, Wang S, Li M, Huang P, Dai J. Noncoplanar intensity-modulated radiation therapy for young female patients with mediastinal lymphoma. J Appl Clin Med Phys. 2012 Nov 8;13(6):3769. doi: 10.1120/jacmp.v13i6.3769. PMID: 23149772; PMCID: PMC5718536.
[18] Yu VY, Landers A, Woods K, Nguyen D, Cao M, Du D, Chin RK, Sheng K, Kaprealian TB. A Prospective 4π Radiation Therapy Clinical Study in Recurrent High-Grade Glioma Patients. Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):144-151. doi: 10.1016/j.ijrobp.2018.01.048. Epub 2018 Jan 31. PMID: 29619962.